Regular Article

British Journal of Cancer (2001) 84, 443–451. doi:10.1054/bjoc.2000.1599 www.bjcancer.com
Published online 13 February 2001

The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients

A Gochi1, K Orita1, S Fuchimoto1, N Tanaka1 and N Ogawa1

1First Department of Surgery, Okayama University Medical School 2-5-1, Shikata-cho, Okayama, Japan

Received 21 December 1999; Revised 25 July 2000; Accepted 1 November 2000.

Top

Abstract

To investigate, by a multi-institutional randomized trial, the prognostic significance of the augmentation of tumour-infiltrating lymphocytes (TILs) by preoperative intratumoral injection of OK-432 (OK-432 it), a bacterial biological response modifier, in patients with gastric cancer. The 10-year survival and disease-free survival were examined and analysis of the factors showing survival benefit was performed. 370 patients who had undergone curative resection of gastric cancer were enrolled in this study and followed up for 10 years postoperatively. Patients were randomized into either an OK-432 it group or a control group. Ten Klinishe Einheit (KE) of OK-432 was endoscopically injected at 1 to 2 weeks before the operation in the OK-432 it group. Both groups received the same adjuvant chemoimmunotherapy consisting of a bolus injection of mitomycin C (0.4 mg kg-1i.v.) and administration of tegafur and OK-432 from postoperative day 14 up to 1 year later. Tegafur (600 mg day-1) was given orally and OK-432 (5 KE/2 weeks) was injected intradermally for a maintenance therapy. The TILs grades in resected tumour specimens and presence of metastasis and metastatic pattern in dissected lymph nodes were examined. Multivariate analysis was performed to determine the efficacy of OK-432 it on prognostic factors. All patients were followed up for 10 years. The overall 5- and 10-year survival rates and disease-free survival rates of the OK-432 it group were not significantly higher than those of the control group. However, OK-432 it significantly increased the 5- and 10-year survival rates of patients with stage IIIA + IIIB, moderate lymph node metastasis (pN2), and positive TILs. OK-432 it was most effective at prolonging the survival of patients who had both positive TILs and lymph node metastasis. The OK-432 it group with positive TILs showed a significant decrease in metastatic lymph node frequency and in the number of lymph node micro- metastatic foci when compared to the control group. This study showed that only one time preoperative OK-432 it, particularly when it triggers TILs, is effective for reduction of regional lymph node metastasis. OK-432 it probably acts partly by eliminating micro-metastatic foci in lymph nodes. Preoperative intratumoral injection of OK-432 is technically very easy and has no serious adverse effects, so it is a promising form of neoadjuvant immunotherapy for advanced gastric cancer. © 2001 Cancer Research Campaign

Keywords:

intratumoral injection, OK-432 (picibanil), medical lymphadenectomy, preoperative immunotherapy

Top

References

  1. Akura Y, Tanaka N, Kobayashi G, Gotch K, Gouchi A, Kamitani S, Gangi J and Orita K (1986) The effects of intratumoral OK-432 injection in gastric cancer patients. New Application of OK-432, Tobe T (ed), Excepta Medica: Tokyo
  2. Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Abe R, Watanabe D, Matsuoka H, Ueo H1 and Akiyoshi T (1992) A trial of adjuvant chemoimmunotherapy with mitomycin C and OK-432 for stage III gastric carcinoma. J Surg Oncol 50: 187–189
  3. Black MM, Opler RS and Speer DF (1956) Structural representations of tumor–host relationships in gastric carcinoma. Surg Gynec Obstet 102: 599–603
  4. Cervical Cancer Immunotherapy Group (1987) Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cancer 60: 2349–2402
  5. Frost P, Ng CP, Belldegrun A and Bonavida B (1997) Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAF)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 180: 70–83 | Article | PubMed |
  6. Gotoh K, Gouchi A, Akura Y, Tanaka N and Orita K (1991) Augmentation of cytotoxicity of tumor infiltrating lymphocytes by biological response modifiers. Int J Immunopharmacol 13: 485–492
  7. Grem JL (1996) 5-Fluoropyrimidines. Cancer Chemotherapy and Biotherapy: Principles and Practice, Chabner BA, Longo BL (eds), Lippincott-Raven: Philadelphia, New York
  8. Howson CP, Hiyama T and Wynder EL (1985) The decline in gastric cancer: Epidemiology of an unplanned triumph. Epidemiol Rev 8: 1–27, (1986).
  9. Ichimura O, Suzuki S, Saito M, Saito M, Sugawara Y and and ISHIDANAugmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol 7: 263–270
  10. Ikeda H, Sato N, Matsuura A, Sasaki A, Takahashi S, Kozutsumi D, Kobata T, Okumura K, Wada Y, Hirata K and Kikuchi K (1996) Clonal dominance of human autologous cytotoxic T lymphocytes against gastric carcinoma: Molecular stability of CDR3 structure of T cell receptor alphabeta gene. Int Immunol 8: 75–82
  11. Inokuchi K, Hattori T, Taguchi T, Abe O and Ogawa N (1984) Postoperative adjuvant chemotherapy of gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer 53: 2393–2397
  12. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT and Finn OJ (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151: 3693–3703 | PubMed | ISI | ChemPort |
  13. Ishii Y, Yamaoka H, Toh K and Kikuchi K (1976) Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Jpn J Cancer Res 67: 115–119
  14. Itoh K, Tilden AB and Balch CM (1986) Interleukin-2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanoma. Cancer Res 46: 3011–3017 | PubMed | ISI | ChemPort |
  15. Kagi D, Vignaux F, Ledermann B, Depraetere V, Nagata S, Hengartner H and Golstein P (1994) Fas and perforin pathway as major mechanisms of T-cell mediated cytotoxicity. Science 265: 528–530 | Article | PubMed | ISI | ChemPort |
  16. Kataoka K, Naomoto Y and Orita K (1991) In vitro induction of perforin mRNA and cytotoxic activities in human splenocytes by streptococcal preparation, OK-432. Jpn J Clin Oncol 21: 330–333
  17. Khalili H, Gal and D Menzin AW (1998) The oligoclonality and ctyokine secretion in TIL and PBMC of patients with ovarian cancer. FASEB J 12: A890, (abstr)
  18. Lin CC, Walsh CM and Young JD (1995) Perforin: structure and function. Immunol Today 16: 194–201 | Article | PubMed | ChemPort |
  19. Lopez C, Feiner H, Rao TD, Shapiro R, Marks JR and Frey AB (1998) Repression of IL-2 mRNA translation in primary human breast cancer tumor-infiltrating lymphocytes. Cell Immunol 190: 141–155
  20. Lowin B, Hahne M, Mattmann C and Tschopp J (1994) Cytolytic T-cell ghjjkcytotoxicity in mediated through perforin and Fas lytic pathways. Nature 370: 650–652 | Article | PubMed | ISI | ChemPort |
  21. MacCarty WC and Mahle AE (1921) Relation of differentiation and lymphocytic infiltration to postoperation longevity in gastric carcinoma. J Lab Clin Med 6: 473–480
  22. Maehara Y, Moriguchi S and Sakaguchi Y (1991) Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 45: 169–172
  23. Maguri HC Jr, Ketcha KA and Lattime EC (1997) Neutralizing anti-IL-10 antibody upregulates the induction and elicitation of contact hypersensitivity. J Interferon Cytokine Res 17: 763–768 | PubMed | ChemPort |
  24. Miwa H, Gohchi A, Moriyasu F and Orita K (1984) Increase in T cell infiltration in carcinoma tissue and regional lymph node reaction to gastric cancer after local injection of immunomodulators before gastrectomy. Manipulation of Host Defense Mechanisms, Aoki T, Tsubura E, Urushizaki IExcepta Medica APCS 38: 13–22
  25. Moriyasu F, Gouchi A, Iijima T, Kouno R, Sunami M and Orita K (1985) Intratumoral administration of immune modulator PSK (Krestin) and its effect on lymphocyte population present in tumor and peripheral blood. Recent Advances in Chemotherapy, Ishigami J (ed), University of Tokyo Press: Tokyo pp. 754–765
  26. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122–1126 | Article | PubMed | ISI | ChemPort |
  27. Niimoto M, Hattori T, Ito I, Tamada R, Inokuchi K, Orita K, Furue H, Ogawa N, Toda T and Furusawa M (1984) Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer. A randomized controlled study of the MMC + tegafur regimen with or without levamisole Report 1. Cancer Immunol Immunother 18: 13–18
  28. Noguchi M and Miyazaki I (1996) Prognostic significance and surgical management of lymph node metastasis in gastric cancer. Br J Surg 83: 156–161
  29. Saito M, Ebina T, Koi M, Yamaguchi T, Kawada Y and Ishida N (1982) Induction of IFN-gamma in mouse spleen cell by OK-432, a preparation of streptococcus pyogenes. Cell Immunol 68: 187–192
  30. Sato M, Harada K, Yoshida Y, Yura Y, Azuda M, lga H and Bendo TKousaataTakegama (1997) Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: Association of the therapeutic effect with differentiation and apoptosis in cancer cells. Apoptosis 2: 227–238
  31. Schenidel DJ, Gamsbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmler G and Segrodo OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor infiltrating lymphocytes. J Immunol 151: 4209–4220 | PubMed | ISI | ChemPort |
  32. Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P and Meyer HJ (1993) Prognostic relevance of systemic lymph node dissection in gastric carcinoma German Gastric Carcinoma Study Group. Br J Surg 80: 1015–1018 | PubMed | ISI | ChemPort |
  33. Slovin SF, Lackman RD, Ferrone S, Kiely PE and Matstrangelo MJ (1986) Cellular immune response to human sarcoma; cytotoxic T cell clone reactive with autologous sarcomas. J Immunol 137: 3042–3048
  34. Stat BITE (1998) Stomach cancer mortality trends in U.S. men and women. J Natl Cancer Inst 90: 185
  35. Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S, Okamura S, Sato K and Orita K (1994) Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A Randomized Trial. Cancer 74: 3097–3103
  36. The Japanese Gastric Cancer Study Group (1981) Gastric cancer registry in Japan – 5 year survival rate of cases between 1963 and 1966. Jpn J Cancer Clin 27: 543–563
  37. Toda K, Shiraishi T, Hirotsu T, Fukuyama K, Mineta T, Kawaguchi S and Tabuchi K (1996) The cytocidal activity of OK-432-activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system. Jpn J Cancer Res 87: 972–976
  38. Topalian SL, Soloman D and Rosenberg SA (1989) Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714–3725 | PubMed | ISI | ChemPort |
  39. Uchida A and Mickshe M (1983) Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK-432. J Natl Cancer Inst 71: 673–680 | PubMed | ChemPort |
  40. Watanabe Y and Iwa T (1984) Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 53: 248–253
  41. Yamamoto A, Nagamatsu M, Usami H, Sugawara Y, Watanabe N and Niitsu YUrushizaki (1986) Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacol 11: 79–86
  42. Yang KD, Stone RM, Lee CS, Chao TY, Cheng SN and Shaio MF (1992) Effect of picibanil (OK-432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother 35: 277–282 | Article | PubMed | ChemPort |
  43. Yasumura S, Weidman E, Hirabayashi H, Johnson JT, Herberman RB and Whiteside TL (1994) HLA restriction and T-cell-receptor V6 gene expression of cytotoxic T lymphocytes reactive with human squamous cell carcinoma of the head and neck. Int J Cancer 57: 297–305